2. Disease Areas
  3. Cancer Inflammation or Immune System Disease
  4. Breast Cancer Cancer Immunology
  5. Immunotherapy for Breast Cancer

Immunotherapy for Breast Cancer

Breast cancer is a heterogeneous disease with diverse molecular subtypes—HR+/HER2−, HER2+, and triple-negative breast cancer (TNBC)—each exhibiting distinct prognoses and treatment responses. Once considered immunologically "cold" and unresponsive to immunotherapy, breast cancer has emerged as a candidate for immune-based treatments, particularly in TNBC, where pembrolizumab combined with chemotherapy has demonstrated clinical efficacy in both neoadjuvant and advanced settings. This advancement marks a pivotal shift in the therapeutic landscape, prompting ongoing research into combination strategies involving immune checkpoint inhibitors and chemotherapy. Despite progress, breast cancer remains a leading cause of cancer-related mortality, with rising incidence among younger women, underscoring the need for innovative therapies. Biomarkers such as PD-L1 Combined Positive Score, tumor mutation burden (TMB), and tumor-infiltrating lymphocytes (TILs) are being actively investigated to guide patient selection and optimize immunotherapy outcomes, highlighting the importance of precision medicine in advancing treatment paradigms across all breast cancer subtypes.

Immunotherapy for Breast Cancer (2):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0260
    Epmedin C 110642-44-9 99.47%
    Epmedin C (Epimedin-C; Baohuoside-VI) is an orally active anti-inflammatory agent and immunomodulator that binds to multiple key proteins including UCP1, Caspase-1, CDK2 and Keap1. Epmedin C inhibits epithelial cell proliferation by disrupting the complex function of CDK2/Cyclin E. Epmedin C also upregulates Nrf2 expression, reduces ROS levels and inhibits pro-inflammatory cytokine secretion, thereby effectively restoring antibody production and alleviating tissue damage. Epmedin C has good safety with no hepatotoxicity or skin sensitization, and it has been used in studies on diseases such as obesity, Deoxynivalenol (HY-N6684)-induced immunotoxicity and mammary hyperplasia.
    Epmedin C
  • HY-N17440
    2-Methoxyjuglone 15127-94-3
    2-Methoxyjuglone, a naphthoquinone, is an apoptosis inducer. 2-Methoxyjuglone activates caspase-9 and caspase-3 via the mitochondrial cytochrome c-dependent intrinsic apoptosis cascade. 2-Methoxyjuglone increases pro-apoptotic Bax levels, decreases anti-apoptotic Bcl-2 levels, and promotes mitochondrial cytochrome c release. 2-Methoxyjuglone induces apoptosis morphological features, early apoptosis, S-phase and G2/M-phase cell cycle arrest, and DNA double-strand breaks. 2-Methoxyjuglone exerts activity against Gram-positive bacteria, pathogenic fungi, and phytopathogenic fungi. 2-Methoxyjuglone can be used for the research of hepatocellular carcinoma, osteosarcoma, colon adenocarcinoma, breast cancer, fungal infection, bacterial infection.
    2-Methoxyjuglone